HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Leaves FDA With Final Thought On What To Do About Cosmetics

Executive Summary

Addressing for the last time the House Appropriations subcommittee with FDA oversight, Commissioner Scott Gottlieb shared his vision for sharpening cosmetics oversight in the absence of significant new resources.

You may also be interested in...



Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform

Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.

ICMAD: Federal Cosmetics Legislation Without National Uniformity Not In Industry’s Interest

If the goal of bills like the proposed Personal Care Products Safety Act is to shore up consumers’ trust in the safety of cosmetic products, national uniformity is an indispensable component, says eos Products President Sanjiv Mehra, chairman of ICMAD’s board.

Gottlieb's Parting Words For US FDA: 'Be Willing To Push' For Major Policy Changes

Outgoing Commissioner tells staff, “No phrase bothered me more than when I heard people say to me they didn’t want to do something important because they wanted to ‘preserve their political capital.’” FDA should not to worry about spending political capital, Gottlieb argued, because it is replenished upon accomplishing important things.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel